Abstract:Purpose This study aimed to investigate the prognostic significance of pretreatment dynamic contrast-enhanced (DCE)-MRI parameters concerning tumor response following induction immunochemotherapy and survival outcomes in patients with locally advanced non-small cell lung cancer (NSCLC) who underwent immunotherapy-based multimodal treatments. Material and methods Unresectable stage III NSCLC patients treated by induction immunochemotherapy, concurrent chemoradiotherapy (CCRT) with or without consolidative immunotherapy from two prospective clinical trials were screened. Using the two-compartment Extend Tofts model, the parameters including K trans , K ep , V e , and V p were calculated from DCE-MRI data. The apparent diffusion coefficient was calculated from diffusion-weighted-MRI data. The receiver operating characteristic (ROC) curve and the area under the curve (AUC) were used to assess the predictive performance of MRI parameters. The Cox regression model was used for univariate and multivariate analysis. Results 111 unresectable stage III NSCLC patients were enrolled. Patients received two cycles of induction immunochemotherapy and CCRT, with or without consolidative immunotherapy. With the median follow-up of 22.3 months, the median progression-free survival (PFS) and overall survival (OS) were 16.3 and 23.8 months. The multivariate analysis suggested that Eastern Cooperative Oncology Group score, TNM stage and the response to induction immunochemotherapy were significantly related to both PFS and OS. After induction immunochemotherapy, 67 patients (59.8%) achieved complete response or partial response and 44 patients (40.2%) had stable disease or progressive disease. The K trans of primary lung tumor before induction immunochemotherapy yielded the best performance in predicting the treatment response, with an AUC of 0.800. Patients were categorized into two groups: high-K trans group (n=67, K trans >164.3×10 −3 /min) and low-K trans group (n=44, K trans ≤164.3×10 −3 /min) based on the ROC analysis. The high-K trans group had a significantly higher objective response rate than the low-K trans group (85.1% (57/67) vs 22.7% (10/44), p<0.001). The high-K trans group also presented better PFS (median: 21.1 vs 11.3 months, p=0.002) and OS (median: 34.3 vs 15.6 months, p=0.035) than the low-K trans group. Conclusions Pretreatment K trans value emerged as a significant predictor of the early response to induction immunochemotherapy and survival outcomes in unresectable stage III NSCLC patients who underwent immunotherapy-based multimodal treatments. Elevated K trans values correlated positively with enhanced treatment response, leading to extended PFS and OS durations.

Decline of Tumor Vascular Function as Assessed by Dynamic Contrast-Enhanced Magnetic Resonance Imaging Is Associated With Poor Responses to Radiation Therapy and Chemotherapy

Noninvasive Monitoring of Microvascular Changes with Partial Irradiation Using Dynamic Contrast-Enhanced and Blood Oxygen Level-Dependent Magnetic Resonance Imaging.

Dynamic Contrast-Enhanced Computed Tomography Functional Imaging for the Evaluation of Tumor Angiogenesis in Patients with Lung Carcinoma

Dynamic Contrast-Enhanced Magnetic Resonance Imaging Biomarkers Predict Survival and Response in Hepatocellular Carcinoma Patients Treated with Sorafenib and Metronomic Tegafur/uracil.

Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma

Value of Dynamic MRI in Monitoring the Microenvironmental Changes of Anti-Vascular Therapy in a Xenograft Model

Evaluation of Therapeutic Effect of Tumor-Targeted Therapy

Correlation of K trans derived from dynamic contrast-enhanced MRI with treatment response and survival in locally advanced NSCLC patients undergoing induction immunochemotherapy and concurrent chemoradiotherapy

DCE-MRI Perfusion and Permeability Parameters as predictors of tumor response to CCRT in Patients with locally advanced NSCLC

Quantitative Assessment of Vasculature with DCE-MRI in Nasopharyngeal Carcinomas Following Radiotherapy and Its Value for Efficacy Evaluation

Evaluation of therapeutic effect of tumor-targeted therapy.

Correlation between quantitative perfusion histogram parameters of Dynamic Contrast-Enhanced MRI and tumor tis-sue microvessel density in patients with lung cancer

Evaluation of Tracer Kinetic Parameters in Cervical Cancer Using Dynamic Contrast-Enhanced MRI As Biomarkers in Terms of Biological Relevance, Diagnostic Performance and Inter-Center Variability.

Vascular response patterns to targeted therapies in murine breast cancer models with divergent degrees of malignancy

Supporting Infortmation from Monitoring Tumor Response to Antivascular Therapy Using Non-Contrast Intravoxel Incoherent Motion Diffusion-Weighted MRI

Characterizing At-Risk Voxels by Using Perfusion Magnetic Resonance Imaging for Cervical Cancer During Radiotherapy.

The Role of Dynamic Contrast-enhanced MRI for Evaluating Therapeutic Effect for NSCLC Patients with Chemotherapy or Chemoradiotherapy

Tumor radiomic heterogeneity: Multiparametric functional imaging to characterize variability and predict response following cervical cancer radiation therapy.

Early Assessment of Response to Chemotherapy in Lung Cancer Using Dynamic Contrast-Enhanced MRI: a Proof-of-concept Study

Correlations of 3T DCE-MRI quantitative parameters with microvessel density in a human-colorectal-cancer xenograft mouse model

Characterizing Tumor Heterogeneity with Functional Imaging and Quantifying High-Risk Tumor Volume for Early Prediction of Treatment Outcome: Cervical Cancer As a Model